Long‐Term Chronic Lung Allograft Dysfunction‐Free Survival Following Lung Transplant in the Presence of Donor‐Specific Antibodies
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Benjamin Grobman und 11 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Lung Transplantation, Isoantibodies, Graft Rejection, Tissue Donors. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Highly sensitized patients with advanced lung disease, who are more often Black and Hispanic women, are at increased risk for waitlist death. In 2012, we implemented a protocol to cross any pre‐transplant donor‐specific antibody (DSA), so long as a prospective complement‐dependent cytotoxicity (CDC) crossmatch was negative. We report long‐term outcomes, including overall survival and chronic lung allograft dysfunction (CLAD)‐free survival.
Methods
This was a single‐institution retrospective cohort study of lung transplant recipients between October 1, 2012–December 31, 2022. We compared overall retransplant‐free survival and CLAD‐free survival between recipients with and without pre‐formed DSA. Secondary outcomes included freedom from acute cellular rejection (ACR) and antibody‐mediated rejection (AMR).
Results
The study cohort included 427 recipients with a median duration of follow‐up of 4.3 years (IQR = 2.1–6.9). Thirty‐three (7.7%) recipients had pre‐transplant DSA with a peak historical mean fluorescence intensity (MFI) of 4200 (IQR = 3000–6600, total range 2100–23 000). The median number of DSA per patient was 1 (IQR = 1–2, total range 1–8). There was no difference in adjusted overall survival between recipients with and without pre‐formed DSA (HR = 1.39, 95% CI = 0.82–2.36, p = 0.22) or adjusted CLAD‐free survival between recipients with and without pre‐formed DSA (HR = 1.07, 95% CI = 0.65–1.75, p = 0.79). Recipients with pre‐formed DSA did not have increased adjusted hazard of ACR (HR = 0.71, 95% CI = 0.29–1.75, p = 0.45) but did have increased adjusted hazard of AMR (HR = 5.02, 95% CI = 2.11–11.95, p < 0.001).
Conclusions
In this moderately‐sized cohort, a protocol of accepting donor offers for lung transplant candidates with pre‐formed DSA but negative CDC crossmatch was not associated with worse overall or CLAD‐free survival, within the limitations of the sample size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harvard Medical School, Boston, Massachusetts, USA.
- Division of Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Tissue Typing Lab, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Benjamin Grobman
Förderung
- NHLBI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Grobman, B., Courtwright, A. M., Yeung, M., Jacob, S., Lee, S., Sheikh, A., Keshk, M., Hackman, A., Coppolino, A., Dunning, J., Sharma, N., & Goldberg, H. J. (2025). Long‐Term Chronic Lung Allograft Dysfunction‐Free Survival Following Lung Transplant in the Presence of Donor‐Specific Antibodies. Clinical Transplantation. https://doi.org/10.1111/ctr.70241
Vancouver
Grobman B, Courtwright AM, Yeung M, Jacob S, Lee S, Sheikh A, et al. Long‐Term Chronic Lung Allograft Dysfunction‐Free Survival Following Lung Transplant in the Presence of Donor‐Specific Antibodies. Clinical Transplantation. 2025. doi:10.1111/ctr.70241
BibTeX
@article{Grobman2025,
author = {Grobman, Benjamin and Courtwright, Andrew M and Yeung, Melissa and Jacob, Selvin and Lee, Stefi and Sheikh, Adil and Keshk, Mohamed and Hackman, Amy and Coppolino, Anthony and Dunning, John and Sharma, Nirmal and Goldberg, Hilary J},
title = {Long‐Term Chronic Lung Allograft Dysfunction‐Free Survival Following Lung Transplant in the Presence of Donor‐Specific Antibodies},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70241}
}
EUVIMED